A Phase 3 interventional study of Oral semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 228 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 10 that started in 2021, is one of 57 in phase 3, and was the 82nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,606 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 18th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2021, is one of 187 in phase 3, and was the 524th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot take part if they are pregnant, breast-feeding or planning to become pregnant during the study period. Women who can get pregnant will be checked for pregnancy via urine tests. Once daily semaglutide tablets (3 mg, 7 mg and 14 mg) are approved for the treatment of type 2 diabetes in the US, in the EU and in some other countries, under the brand name Rybelsus®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).
Drug: Oral semaglutide
Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).
Drug: Oral semaglutide
Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).
Drug: Oral semaglutide
Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
Time frame: Baseline (week 0), week 52
Change From Baseline in Body Weight (Week 52)
Change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 52
Change From Baseline in HbA1c (Week 68)
Change from baseline (week 0) in HbA1c was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
Time frame: Baseline (week 0), week 68
Change From Week 12 in HbA1c (Week 52)
Change in HbA1c was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
Time frame: Week 12, Week 52
Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52)
Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 52
Change From Baseline in FPG (Week 68)
Change from baseline (week 0) in FPG was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 68
Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52)
Percentage of participants who achieved HbA1c \<7.0 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 52
Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68)
Percentage of participants who achieved HbA1c \<7.0 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 68
Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52)
Percentage of participants who achieved HbA1c \<=6.5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 52
Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68)
Percentage of participants who achieved HbA1c \<=6.5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 68
Time to Event Analyses of Rescue Medication
Time to event analyses of rescue medication was evaluated from baseline (week 0) to week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 68
Change From Baseline in Body Weight (Week 68)
Change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 68
Percentage Change From Baseline in Body Weight (Week 52)
Percentage change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 52
Percentage Change From Baseline in Body Weight (Week 68)
Percentage change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 68
Percentage Change From Week 12 in Body Weight (Week 52)
Percentage change in body weight was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Week 12, Week 52
Change From Baseline in Body Mass Index (BMI) (Week 52)
Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 52
Change From Baseline in BMI (Week 68)
Change from baseline (week 0) in BMI was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 68
Change From Baseline in Waist Circumference (Week 52)
Change from baseline (week 0) in waist circumference was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 52
Change From Baseline in Waist Circumference (Week 68)
Change from baseline (week 0) in waist circumference was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline (week 0), week 68
Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52)
Percentage of participants who achieved weight loss \>= 5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 52
Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68)
Percentage of participants who achieved weight loss \>= 5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 68
Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52)
Percentage of participants who achieved weight loss \>= 10 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 52
Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68)
Percentage of participants who achieved weight loss \>= 10 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: At week 68
Change From Baseline in Total Cholesterol (Week 52)
Change from baseline (week 0) in total cholesterol was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 52
Change From Baseline in Total Cholesterol (Week 68)
Change from baseline (week 0) in total cholesterol was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 68
Change From Baseline in Low Density Lipoproteins (LDL) (Week 52)
Change from baseline (week 0) in LDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 52
Change From Baseline in LDL (Week 68)
Change from baseline (week 0) in LDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 68
Change From Baseline in High Density Lipoproteins (HDL) (Week 52)
Change from baseline (week 0) in HDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 52
Change From Baseline in HDL (Week 68)
Change from baseline (week 0) in HDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 68
Change From Baseline in Triglycerides (Week 52)
Change from baseline (week 0) in triglycerides was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 52
Change From Baseline in Triglycerides (Week 68)
Change from baseline (week 0) in triglycerides was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
Time frame: Baseline, Week 68
Number of Adverse Events
An adverse event (AE) defined as any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or disease (new or exacerbated) temporally associated with the use of an investigational medicinal products (IMP). Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: From baseline (week 0) up to week 73
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 Milligram Per Decilitre [mg/dL]) or Severe Hypoglycaemic Episodes (Level 3)
Hypoglycaemic episodes were classified according to the American Diabetes Association 2018/ International Hypoglycaemia Study Group 2017, where glycemic criteria for level 2 was \< 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: From baseline (week 0) up to week 68
Change From Baseline in Systolic Blood Pressure (Week 52)
Change from baseline (week 0) in systolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: Baseline (week 0), week 52
Change From Baseline in Systolic Blood Pressure (Week 68)
Change from baseline (week 0) in systolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: Baseline (week 0), week 68
Change From Baseline in Diastolic Blood Pressure (Week 52)
Change from baseline (week 0) in diastolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: Baseline (week 0), week 52
Change From Baseline in Diastolic Blood Pressure (Week 68)
Change from baseline (week 0) in diastolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: Baseline (week 0), week 68
Change From Baseline in Pulse (Week 52)
Change from baseline (week 0) in pulse at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: Baseline (week 0), week 52
Change From Baseline in Pulse (Week 68)
Change from baseline (week 0) in pulse at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
Time frame: Baseline (week 0), week 68
The trial was conducted in 14 countries (184 sites screened/177 randomised participants) as follows: Australia: 7/6; Bulgaria: 15/15; Canada: 13/13; Croatia: 5/5; Czech Republic: 5/5; Estonia: 6/5; Germany: 8/8; Hungary: 9/9; India: 20/20; Poland: 18/18; Slovakia: 9/9; Slovenia: 5/5; Taiwan: 2/2; United States: 62/57. In addition, Bulgaria (1 site), Canada (1 site), Croatia (1 site) and Poland (1 site) were approved by the institutional review board, but did not randomise any participant.
| Milestone | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Started | 536 | 535 | 535 |
| Treated | 534 | 534 | 534 |
| Full analysis set (fas) | 536 | 535 | 535 |
| Safety analysis set (sas) | 534 | 534 | 534 |
| Completed | 507 | 490 | 505 |
| Not completed | 29 | 45 | 30 |
| Withdrew: Site closure | 0 | 2 | 0 |
| Withdrew: Physician decision | 2 | 2 | 2 |
| Withdrew: Death | 1 | 6 | 2 |
| Withdrew: Lost to follow-up | 9 | 19 | 14 |
| Withdrew: Withdrawal by subject | 17 | 16 | 12 |
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
| Percentage point of HbA1c | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) | -1.5 ± 1.3 | -1.9 ± 1.3 | -2.1 ± 1.4 |
Change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Kilogram (Kg) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Body Weight (Week 52) | -4.4 ± 5.2 | -7.1 ± 6.8 | -8.3 ± 7.5 |
Change from baseline (week 0) in HbA1c was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
| Percentage point of HbA1c | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in HbA1c (Week 68) | -1.5 ± 1.3 | -1.8 ± 1.3 | -2.0 ± 1.4 |
Change in HbA1c was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment. Percentage point refers to arithmetic difference between two percentages.
| Percentage point of HbA1c | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Week 12 in HbA1c (Week 52) | -0.4 ± 1.2 | -0.8 ± 1.1 | -1.0 ± 1.2 |
Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| millimole per litre (mmol/L) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) (Week 52) | -2.4 ± 3.4 | -3.0 ± 3.5 | -3.2 ± 3.4 |
Change from baseline (week 0) in FPG was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in FPG (Week 68) | -2.4 ± 3.4 | -3.0 ± 3.7 | -3.2 ± 3.4 |
Percentage of participants who achieved HbA1c \<7.0 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of Participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c Less Than (<) 7.0 (Percent [%]) (Week 52) | 39 | 50.5 | 63 |
Percentage of participants who achieved HbA1c \<7.0 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of Participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c < 7.0 % (Week 68) | 39.2 | 49.9 | 58.9 |
Percentage of participants who achieved HbA1c \<=6.5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of Participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c Less Than or Equal to (<=) 6.5 % (Week 52) | 25.8 | 39.6 | 51.2 |
Percentage of participants who achieved HbA1c \<=6.5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of Participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c <= 6.5 % (Week 68) | 23.6 | 35.8 | 46.2 |
Time to event analyses of rescue medication was evaluated from baseline (week 0) to week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Weeks | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Time to Event Analyses of Rescue Medication | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Kg | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Body Weight (Week 68) | -4.5 ± 5.5 | -7.1 ± 7.4 | -8.2 ± 8.1 |
Percentage change from baseline (week 0) in body weight was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage change in body weight | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage Change From Baseline in Body Weight (Week 52) | -4.7 ± 5.4 | -7.3 ± 6.6 | -8.5 ± 7.3 |
Percentage change from baseline (week 0) in body weight was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage change in body weight | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage Change From Baseline in Body Weight (Week 68) | -4.7 ± 5.6 | -7.2 ± 7.1 | -8.4 ± 7.7 |
Percentage change in body weight was evaluated from week 12 to week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage change in body weight | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage Change From Week 12 in Body Weight (Week 52) | -1.5 ± 3.6 | -3.8 ± 5.4 | -5.4 ± 6.1 |
Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| kilogram per square metre (kg/m^2) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) (Week 52) | -1.6 ± 1.8 | -2.5 ± 2.5 | -2.9 ± 2.6 |
Change from baseline (week 0) in BMI was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| kg/m^2 | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in BMI (Week 68) | -1.6 ± 1.9 | -2.5 ± 2.7 | -2.9 ± 2.8 |
Change from baseline (week 0) in waist circumference was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| centimetre (cm) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Waist Circumference (Week 52) | -4 ± 7 | -5 ± 7 | -6 ± 7 |
Change from baseline (week 0) in waist circumference was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| cm | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Waist Circumference (Week 68) | -4 ± 6 | -6 ± 7 | -7 ± 8 |
Percentage of participants who achieved weight loss \>= 5 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss Greater Than or Equal to (>=) 5 % (Week 52) | 41 | 60 | 67.5 |
Percentage of participants who achieved weight loss \>= 5 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss >= 5 % (Week 68) | 42.2 | 58.5 | 65.7 |
Percentage of participants who achieved weight loss \>= 10 % at week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 52) | 13.9 | 29 | 37.2 |
Percentage of participants who achieved weight loss \>= 10 % at week 68 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| Percentage of participants | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss >= 10 % (Week 68) | 14.3 | 29.4 | 34.7 |
Change from baseline (week 0) in total cholesterol was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Total Cholesterol (Week 52) | -0.04 ± 0.96 | -0.15 ± 1.10 | -0.06 ± 0.94 |
Change from baseline (week 0) in total cholesterol was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Total Cholesterol (Week 68) | -0.03 ± 0.99 | -0.08 ± 1.05 | -0.06 ± 1.00 |
Change from baseline (week 0) in LDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Low Density Lipoproteins (LDL) (Week 52) | 0.04 ± 0.75 | -0.01 ± 0.85 | 0.11 ± 0.76 |
Change from baseline (week 0) in LDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in LDL (Week 68) | 0.07 ± 0.80 | 0.06 ± 0.85 | 0.08 ± 0.79 |
Change from baseline (week 0) in HDL was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in High Density Lipoproteins (HDL) (Week 52) | 0.06 ± 0.18 | 0.07 ± 0.19 | 0.08 ± 0.18 |
Change from baseline (week 0) in HDL was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in HDL (Week 68) | 0.06 ± 0.19 | 0.08 ± 0.21 | 0.09 ± 0.20 |
Change from baseline (week 0) in triglycerides was evaluated at week 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Triglycerides (Week 52) | -0.46 ± 1.77 | -0.65 ± 2.08 | -0.71 ± 1.40 |
Change from baseline (week 0) in triglycerides was evaluated at week 68. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of additional anti-diabetic medication or discontinuation of trial treatment.
| mmol/L | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Triglycerides (Week 68) | -0.51 ± 1.77 | -0.65 ± 2.06 | -0.70 ± 1.43 |
An adverse event (AE) defined as any unfavourable and unintended sign, including an abnormal laboratory finding, symptom or disease (new or exacerbated) temporally associated with the use of an investigational medicinal products (IMP). Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| Events | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Number of Adverse Events | 1641 | 2055 | 2115 |
Hypoglycaemic episodes were classified according to the American Diabetes Association 2018/ International Hypoglycaemia Study Group 2017, where glycemic criteria for level 2 was \< 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| Count of episodes | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Level 2 | 65 | 44 | 35 |
| Level 3 | 0 | 0 | 1 |
Change from baseline (week 0) in systolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| millimetres of mercury (mmHg) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (Week 52) | -4 ± 14 | -6 ± 13 | -6 ± 14 |
Change from baseline (week 0) in systolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| mmHg | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (Week 68) | -4 ± 13 | -6 ± 13 | -5 ± 13 |
Change from baseline (week 0) in diastolic blood pressure at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| mmHg | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (Week 52) | -2 ± 8 | -2 ± 8 | -2 ± 8 |
Change from baseline (week 0) in diastolic blood pressure at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| mmHg | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (Week 68) | -3 ± 8 | -3 ± 8 | -2 ± 8 |
Change from baseline (week 0) in pulse at week 52 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| beats per minute (beats/min) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Pulse (Week 52) | 2 ± 10 | 2 ± 10 | 3 ± 11 |
Change from baseline (week 0) in pulse at week 68 are presented. Results are based on the data from the on-treatment observation period, which was the time period when a participant was on trial treatment, including any period after initiation of rescue medication.
| beats/min | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Change From Baseline in Pulse (Week 68) | 1 ± 10 | 2 ± 10 | 2 ± 10 |
Collected over Week 0 to week 73. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Semaglutide 14 mg | 2/534 (0.4%) | 53/534 (9.9%) | 277/534 (51.9%) |
| Oral Semaglutide 25 mg | 6/534 (1.1%) | 57/534 (10.7%) | 294/534 (55.1%) |
| Oral Semaglutide 50 mg | 2/534 (0.4%) | 44/534 (8.2%) | 314/534 (58.8%) |
| Event | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 4/534 | 3/534 | 1/534 |
| COVID-19Infections and infestations | 3/534 | 0/534 | 3/534 |
| Atrial fibrillationCardiac disorders | 2/534 | 1/534 | 1/534 |
| COVID-19 pneumoniaInfections and infestations | 2/534 | 2/534 | 2/534 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 2/534 | 0/534 | 0/534 |
| Circulatory collapseVascular disorders | 0/534 | 2/534 | 0/534 |
| Coronary artery diseaseCardiac disorders | 2/534 | 1/534 | 1/534 |
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 0/534 | 2/534 | 0/534 |
| Ischaemic strokeNervous system disorders | 1/534 | 2/534 | 0/534 |
| Myocardial infarctionCardiac disorders | 2/534 | 1/534 | 0/534 |
| Event | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg |
|---|---|---|---|
| NauseaGastrointestinal disorders | 96/534 | 145/534 | 146/534 |
| VomitingGastrointestinal disorders | 52/534 | 91/534 | 97/534 |
| DiarrhoeaGastrointestinal disorders | 66/534 | 69/534 | 76/534 |
| COVID-19Infections and infestations | 63/534 | 64/534 | 66/534 |
| Decreased appetiteMetabolism and nutrition disorders | 38/534 | 39/534 | 58/534 |
| Diabetic retinopathyEye disorders | 41/534 | 26/534 | 35/534 |
| ConstipationGastrointestinal disorders | 40/534 | 35/534 | 33/534 |
| HeadacheNervous system disorders | 34/534 | 28/534 | 38/534 |
| Abdominal pain upperGastrointestinal disorders | 14/534 | 32/534 | 22/534 |
| DyspepsiaGastrointestinal disorders | 28/534 | 29/534 | 30/534 |
Full analysis set (FAS) included all randomised participants.
| Age, Continuous(Years) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg | Total |
|---|---|---|---|---|
| Mean | 58.4 ± 10.4 | 58.8 ± 10.7 | 57.6 ± 11.2 | 58.2 ± 10.8 |
| Sex: Female, Male(Participants) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg | Total |
|---|---|---|---|---|
| Female | 211 | 231 | 228 | 670 |
| Male | 325 | 304 | 307 | 936 |
| Ethnicity (NIH/OMB)(Participants) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 38 | 37 | 36 | 111 |
| Not Hispanic or Latino | 498 | 498 | 499 | 1495 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Oral Semaglutide 14 mg | Oral Semaglutide 25 mg | Oral Semaglutide 50 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 85 | 73 | 111 | 269 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 0 | 2 |
| Black or African American | 19 | 22 | 18 | 59 |
| White | 424 | 432 | 398 | 1254 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 6 | 8 | 21 |
Showing the first 100 of 228 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Jan 2021 to primary completion in Mar 2023, 25 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide